Catinazzo Thomas's Form 4 filing
Relay Therapeutics, Inc. (RLAY) · filed Jan 30, 2025
- Accession no.
- 0000950170-25-011327
- Filed
- Jan 30, 2025
- Trade date
- Jan 28-30, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $268.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Catinazzo ThomasCIK 0001818261 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 28, 2025 | Common Stock | SSaleDisposed | −33,753 | $4.63 | −$156,276.39 | 265,473 | Direct | |
| Jan 28, 2025 | Common Stock | SSaleDisposed | −2,283 | $4.63 | −$10,570.29 | 263,190 | Direct | |
| Jan 28, 2025 | Common Stock | AGrant or awardAcquired | +139,141 | $0.00 | $0 | 402,331 | Direct | |
| Jan 29, 2025 | Common Stock | SSaleDisposed | −2,109 | $4.55 | −$9,595.95 | 400,222 | Direct | |
| Jan 30, 2025 | Common Stock | SSaleDisposed | −20,791 | $4.42 | −$91,896.22 | 379,431 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.